RAC 2.20% $1.78 race oncology ltd

RAC media coverage, page-1386

  1. 2,843 Posts.
    lightbulb Created with Sketch. 2893
    Fly on the wall can’t imagine the reaction, hypothetical scenario ; )

    Just want to discuss our development pipeline and keen to get your input.

    Worlds most potent FTO inhibitor otherwise know as CS1, ready to kick off P2 once we review just a 100+ cancer outcomes. We wanted to start off small initially.

    We noticed that Zantrene also protects against cardiotoxicity in not only Dox, AC, Kyprolis… Unlike other cardio protection Zantrene continues to kill and actually synergises with these drugs / overcomes resistance.

    As per triangles report we estimate a $5b annual revenue if we just focus on the US market before we go global.

    BTW the market is sleeping on this we have a modest market cap of $170m USD.

    I’ve got a month of meetings ahead, are you in or are you out?

 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.